Navigation Links
Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
Date:7/23/2013

CHARLESTON, S.C., July 23, 2013 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the completion of its scheduled Pre-IND meeting with the U.S Food and Drug Administration (FDA) for the proposed Investigational New Drug, CL-H1T, as a novel treatment for patients who suffer from migraine pain and migraine induced nausea or vomiting.   

"The Pre-IND meeting with FDA's Division of Neurology Products (DNP) was positive and productive," said Mr. John Ameling, Vice President of Regulatory Affairs at Charleston. "The questions we raised in the Briefing Document were answered and clarified in the meeting. I am confident that Charleston will be able to conduct the Drug Development Program that DNP agreed to and submit an approvable a 505 (b) (2) New Drug Application."  

"From a drug development standpoint, the information we received from FDA during our Pre-IND meeting will facilitate our ability to complete our proposed program on CL-H1T" said Dr. Bill Kozarek, Charleston's Vice President of Product Development.  "I am very excited to advance the CL-H1T program to demonstrate significant benefits for patients who suffer from migraines, relieving pain and reducing or eliminating nausea and vomiting."

About Charleston Laboratories, Inc.

Charleston Laboratories, Inc. is a specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states. Charleston's new products will address Opioid Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy Induced Nausea and Vomiting (CINV), Radiation Induced Nausea and Vomiting (RINV), and Migraine Induced Nausea and Vomiting (MINV).  In addition, Charleston is developing other products without acetaminophen to reduce the potential for liver injury and formulations with abuse deterrent technologies designed to curb misuse and abuse. Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
2. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
3. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
4. Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA Sequencing
5. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
6. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
7. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
8. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
9. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
10. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
11. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, today announced the submission ... New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, ... (KB0120) of Zimeta for the control of pyrexia (fever) ... --> --> The Chemistry, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new ... area. The latest campaign focuses on the fight against breast cancer, fundraising for a ... accepted here . , Carmen is a loving single mother of two boys ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... For ... Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. ... joined dozens of dental professionals, donating their time and skills to help hundreds of ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... an upcoming Feb. 24 webinar that will discuss ways health plans and PBMs ... as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat ...
Breaking Medicine News(10 mins):